J&J halts development of CAR-T cell therapies
Key Questions
Why did J&J halt development of certain CAR-T therapies?
J&J discontinued non-core B-cell lymphoma CAR-T programs as part of a strategic refocus amid a shifting landscape. This allows reallocation of resources toward higher-priority oncology areas.
Which specific CAR-T programs were axed by J&J?
The halted programs are JNJ-9530 and JNJ-4496, previously projected to reach $5 billion peak sales. The decision came despite their best-in-class efficacy data from April.
What is J&J pivoting to after halting these CAR-T programs?
J&J is focusing on CARVYKTI's supplemental New Drug Application, showing 59% efficacy in myeloma. This supports their $50 billion oncology target by 2030.
Halts non-core B-cell lymphoma CAR-T (JNJ-9530/JNJ-4496 $5B peak axed Apr30 despite best-in-class efficacy) pivot to CARVYKTI sNDA +59% myeloma. Strategic refocus amid landscape shift; monitor oncology reallocation/$50B 2030 target.
Sources (2)
Updated May 1, 2026